Internal Medicine · Baltimore, MD
NPI
1477518033
Since 2006
Specialty
Internal Medicine
Code 207R00000X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
600 N Wolfe St
Baltimore, MD, 21287
Phone (410) 955-1725
Groups this clinician bills Medicare through
Medicare paid, 2024
$10K
187 services
Medicare patients, 2024
78
Average age 66
Drug cost, 2024
$3.1M
1,662 prescriptions
Company payments, 2023
$19.81
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Patricia Barditch-Crovo was code 99214 (office e&m - established), 62 times for 44 patients. In total Patricia Barditch-Crovo billed 187 services in 13 codes, and Medicare paid $10K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-01-15.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 62 | 44 | $53.01 | $3,286 |
| 99215 Office E&M - Established | Facility | 50 | 35 | $63.83 | $3,192 |
| 99213 Office E&M - Established | Facility | 26 | 24 | $38.87 | $1,011 |
| 99214 Office E&M - Established | Office | 17 | 11 | $67.82 | $1,153 |
By year: 2022 $16K for 249 services; 2023 $14K for 223 services; 2024 $10K for 187 services.
Medicare prescription drug claims, 2024
In 2024, the drug Patricia Barditch-Crovo prescribed most often to Medicare patients was Biktarvy (Bictegrav/Emtricit/Tenofov Ala), with 217 prescriptions and refills. In total Patricia Barditch-Crovo wrote 1,662 Medicare prescriptions that cost $3.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 217 | 217 | 33 | $813K |
| Darunavir Generic | 151 | 151 | 14 | $142K |
| Prezcobix Darunavir/Cobicistat | 134 | 139 | 15 | $321K |
| Ritonavir Generic | 134 | 164 | 16 | $14K |
| Tivicay Dolutegravir Sodium | 102 | 105 | 17 | $299K |
| Juluca Dolutegravir/Rilpivirine | 101 | 101 | 12 | $334K |
| Dovato Dolutegravir Sodium/Lamivudine | 80 | 80 | Under 11 | $226K |
| Maraviroc Generic | 53 | 53 | Under 11 | $61K |
| Isentress Hd Raltegravir Potassium | 50 | 50 | Under 11 | $92K |
| Pifeltro Doravirine | 49 | 53 | Under 11 | $90K |
| Descovy Emtricitabine/Tenofov Alafenam | 45 | 45 | Under 11 | $95K |
| Lamivudine Generic | 43 | 51 | Under 11 | $4,268 |
| Triumeq Abacavir/Dolutegravir/Lamivudi | 39 | 39 | Under 11 | $143K |
| Valacyclovir Valacyclovir Hcl | 32 | 32 | Under 11 | $856 |
| Atorvastatin Calcium Generic | 24 | 42 | Under 11 | $129 |
Brand drugs: 994 claims; generic drugs: - claims.
Money and other things of value reported by the companies
In 2023, drug and medical device companies paid Patricia Barditch-Crovo $19.81 ($19.81 in general payments such as food, travel and fees) from 1 company. The largest payer was Merck Sharp & Dohme LLC with $19.81.
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC MRK | 1 | $19.81 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.